rescinnamine is an approved drug
Compound class:
Natural product or derivative
Comment: Rescinnamine is an angiotensin-converting enzyme (ACE) inhibitor. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation.
|
|
Classification | |
Compound class | Natural product or derivative |
Approved drug? | Yes |
IUPAC Name |
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
International Nonproprietary Names | |
INN number | INN |
683 | rescinnamine |
Database Links | |
CAS Registry No. | 24815-24-5 |
ChEBI | CHEBI:28572 |
ChEMBL Ligand | CHEMBL1668 |
DrugBank Ligand | DB01180 |
DrugCentral Ligand | 2369 |
GtoPdb PubChem SID | 178103676 |
PubChem CID | 5280954 |
Search Google for chemical match using the InChIKey | SZLZWPPUNLXJEA-QEGASFHISA-N |
Search Google for chemicals with the same backbone | SZLZWPPUNLXJEA |
Search PubMed clinical trials | rescinnamine |
Search PubMed titles | rescinnamine |
Search PubMed titles/abstracts | rescinnamine |
UniChem Compound Search for chemical match using the InChIKey | SZLZWPPUNLXJEA-QEGASFHISA-N |
UniChem Connectivity Search for chemical match using the InChIKey | SZLZWPPUNLXJEA-QEGASFHISA-N |
Wikipedia | Rescinnamine |